Related Experiment Video
Updated: Aug 4, 2025
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
506
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d
Charlotte Fuller1, Zain Chagla1
1McMaster University, Hamilton, Ontario, Canada (C.F., Z.C.).
Annals of Internal Medicine
|April 3, 2023
Insights
This study followed critically ill COVID-19 patients for 180 days, finding no significant differences in long-term outcomes between treatment groups. The REMAP-CAP trial provides crucial data on extended recovery trajectories for severe respiratory illness.
Area of Science:
- Critical care medicine
- Infectious diseases
- Clinical trials
Background:
- The COVID-19 pandemic caused severe respiratory illness, leading to prolonged critical care and uncertain long-term outcomes.
- Understanding the extended recovery course for critically ill patients is essential for optimizing treatment strategies and patient management.
Purpose of the Study:
- To evaluate long-term (180-day) outcomes in critically ill patients with COVID-19.
- To assess the impact of different treatment strategies within the REMAP-CAP trial on extended patient recovery.
Main Methods:
- The study analyzed data from the Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia (REMAP-CAP) trial.
- Critically ill patients with COVID-19 were followed for 180 days to assess various clinical outcomes.
Main Results:
- No significant differences in 180-day mortality were observed between treatment groups.
- Key secondary outcomes, including organ support and recovery milestones, also showed no significant variations across different treatment arms.
Conclusions:
- For critically ill COVID-19 patients, the investigated treatment strategies did not lead to significant differences in long-term (180-day) outcomes.
- The findings underscore the complexity of recovery from severe COVID-19 and the need for continued research into effective interventions.
Abstract
Source Citation:
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.
Related Concept Videos
01:29Acute Respiratory Failure-V
174
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
174
01:21Acute Respiratory Failure-II
298
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
298
01:30Acute Respiratory Failure-III
239
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
239
01:21Acute Respiratory Failure-I
261
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
261
01:23Acute Respiratory Failure-IV
184
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
184
01:26COPD: Management Using Bronchodilators and Corticosteroids
260
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
260